Foresight in cancer care and drug design.
Who We Are
Our company mission is to reduce the uncertainty involved in treating cancer and developing novel cancer therapeutics.
Using our custom developed software ConcR is combining multiple different approaches and data sources together into a single holistic approach for modelling tumour progression. This sets us apart from others in our accuracy and specificity.
The ConcR Team
Matthew Griffiths PhD
What We Do
We offer services to both clinicians and pharmaceutical companies looking to increase the value of their novel oncology therapeutics.
Decision Support Tool
We are developing decision support tools for the treatment of pancreatic ductal adenocarcinoma and triple-negative breast cancer.
And we are interested in broadening to other indications, for example colorectal, prostate and ovarian.
If you want to see a demo of our clinical product or are interested in working collaboratively with us then please contact us below.
Our software identifies complex predictive biomarkers from multi-omic data which can be used to guide clinical trial cohort selection criteria and enrichment strategies, and combination therapy optimisation.
Applied in the pre-clinical - clinical translation phase, our technology can broaden the market access potential of novel therapeutic candidates, shorten pre-clinical R&D time and predict the sensitivity of cell lines to a novel drug.
If you want to see a demo of our technology or speak about collaborative work please contact us below.